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1. Introduction 
1.1 Cancer 
Cancer is a name given to a group of diseases that arise from a single cell when it starts to 
grow abnormally in an uncontrollable manner to form a group of undifferentiated cells, 
known as tumour. Tumour can be classified into two categories; benign and malignant. Not 
all benign tumours are cancerous but all malignant tumours are (Hanahan & Weinberg, 
2000). The main difference between these tumours is benign tumour lack the metastatic 
ability, grows locally and is less harmful. However, some benign tumours can transform 
into malignant tumours that possess the metastatic ability to invade and spread to other 
parts of the body via the blood or lymphatic circulation and form secondary tumour and 
eventually lead to death (Vincent & Gatenby, 2008). 
1.2 Development of cancer (carcinogenesis) 
Cancer develops through a multistep process known as carcinogenesis (Fig 1), which 
includes initiation, promotion and progression (Pitot, 2006). An initiation stage is a 
permanent and irreversible event, which involves one or more cellular changes arising 
upon exposure to carcinogens, which leads to alteration in DNA and may result in a 
mutated cell to divide rapidly (hyperplasia). These transformed (initiated) cells can 
remain harmless, unless exposed to a stimulator, which enhances the tumour to grow into 
a larger mass. This is a reversible process and is known as the promotion stage. The 
progression stage is an irreversible conversion of a benign tumour to become a malignant 
tumour. This carcinogenesis process usually takes 10 years or more to develop and 
usually depends on the internal (life style) and external (environmental) factors of the 
patient (Pitot, 2002). 
1.3 Hallmarks of cancer 
A transformed cell has to acquire six hallmarks in order to be developed into cancer (Fig 2) 
(Hanahan & Weinberg, 2000). Each of these hallmarks is derived upon changes in the 
normal cell’s physiology and interacts with each other to promote malignant growth. The 
conversion from a normal cell to become a transformed cell usually starts from mutations in 
DNA which cause the cells no longer depend on growth signals, thus gaining uncontrolled 
growth and proliferation. The irresponsiveness or insensitivity to anti-growth signals in 
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cancer cells, enables them to evade apoptosis. The mutations in cancer cells can also change 
the normal function of the telomerase, thus give rise to cancer cell a limitless replicative 
potential (Bree et al. 2002; Kim et al. 1994). Tumour invasion, metastasis and angiogenesis 
play important roles in allowing the progression of a malignant tumour, by escaping the 
primary site, invading into blood or lymph circulation, migration to a distant site and finally 
establishing a secondary tumour. 
 
 
 
 
 
 
 
Fig. 1. Three stages of carcinogenesis 
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Fig. 2. The Hallmarks of Cancer (Hanahan & Weinberg, 2000) 
2. Prostate cancer 
Prostate is a gland in the male reproductive system that is responsible for the production 
and storage of seminal fluid. The normal adult human prostate is about the walnut size and 
is located at the neck of the urinary bladder and surrounds part of the urethra. Prostate 
cancer develops when its semen-secreting prostate gland cells are transformed into cancer 
cells, and has been classified as adenocarcinoma. Prostate cancer is one of the most 
commonly diagnosed cancers in men and it is the second leading cause of cancer death after 
lung cancer worldwide. The incidence and mortality rates of prostate cancer are increasing 
in Asia as well as in the United States over the past few decades (National Cancer Institute 
[NCI], 2011). 
2.1 Symptoms & diagnosis 
Prostate cancer will cause male patients to experience difficulties during urination such as 
nocturia, hematuria, dysuria, and will also interfere with sexual functions and 
performance. The high mortality rate in prostate cancer patients is due to late detection as 
prostate cancer is usually asymptomatic or the symptoms appear only during the 
advanced stage of disease. About 50% of prostate cancer patients are usually diagnosed 
with bone metastasis. Table 1 shows several tests for prostate cancer diagnosis in male 
patients by doctor (NCI, 2011). 
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Test Description 
Biopsy 
Removal of small pieces of prostate tissue through rectum 
(transrectal) or skin between scrotum and rectal 
(transperineal) for microscopic examination by urologist, 
oncologist and/or pathologist 
Digital rectal 
examination 
Detect prostate gland abnormalities such as lumps  
Transrectal 
ultrasonography 
High energy ultrasound from probe in the rectum is enable 
to create a picture (sonogram) of the prostate gland to 
examine its abnormalities 
Prostate tumour 
markers 
Detection the abnormal levels of prostate specific antigen 
(PSA) in blood 
Table 1. List of test for the diagnosis of prostate cancer (Source: NCI, USA) 
2.2 Stages 
It is important to determine the stage of prostate tumour in order to plan an effective 
treatment in patient (Table 2). This is because there is a differential response to treatment in 
the different stages of this cancer. To determine accurately the stage of prostate tumour in 
patients, different tests are conducted and all information will be gathered from CT 
(computerised tomography) scan, MRI (magnetic resonance imaging), PSA (prostate-specific 
antigen) test and tumour biopsy (NCI, 2011). 
 
Stage Description 
I Cancer cells are found in prostate gland only and PSA < 10 
II 
 
IIA 
IIA 
Divided to 2 categories; 
 
Found in one half or less than one lobe and PSA < 20 
Found in both lobes of prostate gland and PSA < 20 
III 
Spread beyond the outer layer of prostate gland and may 
spread to seminal vesicle, PSA value is ranging from 2-10. 
IV 
Spread to nearby or other organs such as rectum, bladder and 
bone, any level in PSA  
Table 2. Stages of prostate tumour (Source: NCI, USA) 
2.3 Treatments 
Currently, there are four standard treatments for prostate cancer; watchful waiting, surgery, 
radiation therapy and hormone therapy. In watchful waiting, a patient will be closely 
monitored by doctors and no treatment will be given until symptoms start to appear. While 
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in surgery, prostate gland from patients will be removed before the cancer cells are able to 
spread to other organs. In radiation therapy, high energy X-rays will be used to kill cancer 
cells. Antiandrogens, estrogens and luteinizing hormone-releasing hormone agonists, are 
the few examples used in hormone therapy to stop the cancer cells by disrupt their growth 
and/or kill them. While other treatment includes chemotherapy and proton-beam radiation 
therapy which are used in conjunction with other standard treatments (NCI, 2011). 
2.4 Problems 
Prostate cancer is extremely hard to treat due to several distinct classes of tumour that exhibit 
different responses to treatment. Most of the synthetic anticancer agents such as doxorubicin 
mainly affect the fast-dividing cells of the body and cause side effects such as pain, nausea, 
vomiting, alopecia, and anaemia (CancerBackup, 2003). Nevertheless, prostate cancer cells are 
derived from normal cells and thus, cancer cells have the ability to maintain the usual 
physiological functions to protect themselves from anything that can cause cell destruction. 
Estramustine and mitoxantrone are the only two drugs approved by the US FDA for prostate 
cancer treatment; however, neither showed to increase lifespan of patients (NCI, 2011).  
Therefore, the development of resistance to anticancer drugs by cancer cells is a major 
problem in cancer therapies and has resulted in a high mortality rate in prostate cancer 
patients. About 50% of male prostate cancers patients are diagnosed at advanced stage with 
metastasis into their bone (Uehara et al. 2003; Koeneman et al. 1999). Thus, tumour 
metastasis is a major cause of morbidity and has become a major challenge for a successful 
treatment (Hung et al. 2009). Currently, there is no effective treatment for prostate cancer, so 
intense research is required to obtain new anticancer agents for this cancer. 
3. Natural products 
Herbs and plants-derived medicines have a long history of use in the various treatments 
and now, they still remain as important sources for the development of anticancer drugs. 
More than 3000 plants species have been reported to be involved in the development of 
anticancer drugs (Shoeb, 2006). The exploration of anticancer agents from plant sources has 
started since the 1950s. Since then, extensive research and investigations have been 
conducted and lead to the discovery and development of several anticancer agents derived 
from plant such as taxol, vinblastine and vincristine (Cragg & Newman, 2005). From 1940-
2006, more that 40% of drugs in the market are anticancer agents and 65% of these 
anticancer drugs mimic natural compounds.  
The development of chemoresistant of cancer cells to anticancer drugs have resulted high 
mortality in prostate cancer patients. Thus, scientists have begun to focus on natural-
product as alternative to produce new therapeutic agents in prostate cancer treatments. 
Although, no new plant derived clinical anticancer agents have been launched in market 
recently, but a number of agents are being tested in the preclinical stage such as 
thapsigargin (Cragg & Newman, 2005). 
3.1 Thapsigargin (TG) 
Thapsigargin is a plant-derived anti-tumour agent, isolated from Thapsia garganica L 
(Familly Apiaceae), collected in Mediterranean island of Ibiza. TG can evoke apoptosis in 
prostate cancer cells through the disruption of Ca2+ intracellular levels. In addition, TG can 
completely inhibit tumour growth in prostate tumour bearing nude mouse without causing 
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significant toxicity signs. Currently, TG is tested in preclinical stage against prostate cancer 
(Cragg & Newman, 2005). 
3.2 Turmeric (curcumin) 
Turmeric or known as curcumin is derived from the dried root of a plant (Curcuma longa L.) 
of the ginger family. It possesses a variety of pharmacological effects including anti-oxidant 
and anti-inflammatory activities. It has also been reported to possess anti-cancer effects 
through its inhibition on proliferation and apoptosis induction in wide variety of cancer cell 
lines including breast, lung and prostate cancer cells. The apoptosis induction is due to 
activation of pro-apoptotic proteins (Bax and Bak) and caspases involved in prostate cancer 
cells by turmeric. Currently in human clinical trials, turmeric is administered at dose up at 
10g/day without causing any toxicity signs (Cragg & Newman, 2005; Kuttan et al. 1987). 
4. Phyllanthus 
The plant of the genus Phyllanthus is a small annual plant and is widely distributed 
throughout the tropical and subtropical regions of world (Lee et al. 1996). This plant has a 
long history in medical herbalism system to treat kidney and urinary bladder disturbances. 
Thus, substantial studies on Phyllanthus regarding their chemistry, pharmacological activity 
and clinical effectiveness have been carried out. The extracts of these plants have been 
reported to have pharmacological effects such as antiviral activity against hepatitis B and 
related hepatitis viruses, anti-bacterial activity, anti-hepatotoxic or liver-protecting activity, 
and hypoglycaemia properties (Etta, 2008; Mazumder et al. 2006; Kloucek et al. 2005; Ott et 
al. 1997; Lee et al. 1996; Blumberg et al. 1990; Venkatswaran et al. 1987). 
The anticancer effects of the genus Phyllanthus has been reported in a few papers, for 
instance P. amarus protects the liver from hepatocarcinogenesis and the root extract of P. 
acuminatus exerts growth inhibition in murine P-388 lymphocytic leukemia and B-16 
melanoma cell lines (Pettit et al. 1990; Powis & Moore, 1985). Thus, it is believed that the 
plant genus Phyllanthus might possess anticancer properties against prostate cancer as well.  
 
   
Fig. 3. P.urinaria (Fito Pharma 2011), P.amarus (Siddha Global, 2010) and P.niruri (Nova 
Laboratories Sdn Bhd, 2011). 
4.1 Bioactive compounds 
"Bioactive compound" is a general term to describe the nutritional constituents that are 
contained in plants. These compounds are intensively studied and various reports from 
numerous types of epidemiological and case controlled studies have linked their effects on 
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health such as cardiovascular disease and cancer. Many bioactive compounds have been 
discovered and classified in different groups based on their chemical structure and function 
(Kris-Etherton et al. 2002). For example, phenolic and flavonoid compounds are found in all 
plants such as vegetables and fruits.  
For the detection of bioactive compounds contained in Phyllanthus, HPLC (High 
Performance Liquid Chromatography) and MS-MS (Tandem mass spectrometry) are often 
used. These methods allow the separation and identification of compound from in 
Phyllanthus extracts. Various bioactive compounds have been identified from different 
species of Phyllanthus and are listed in Table 3. Most of these bioactive compounds such as 
gallic acid, gereniin and rutin, possess antioxidant and anticancer effects. 
4.2 Anti-proliferative effects 
One of the hallmarks of cancer is uncontrolled proliferation. Thus, the anti-proliferative 
effect of a substance is referring to the ability of the substance to halt cancer growth by 
inhibiting/killing cancer cells. The anti-proliferative effects of Phyllanthus have been 
detected in different cancer cell lines including breast, lung, melanoma, liver, lung, leukemia 
and prostate (Lee et al. 2011; Tang et al. 2010; Huang et al. 2006, 2004, 2003; Sureban et al. 
2006). The water extract of P.urinaria have been found to possess a selective anti-
proliferative effect on leukemia cells without showing cytotoxicity on normal cells (Huang 
et al. 2004). Similar findings have also been reported by Lee et al (2011) and Tang et al 
(2010), where four plant species of Phyllanthus (P.amarus, P.niruri, P.urinaria and P.watsonii) 
does possesses selective anti-proliferative effects on four different cancer cells; MeWo, A549, 
MCF-7 and PC-3 cell lines, without cytotoxic effects on their respective normal cells. In 
addition, the methanolic extracts of these plants were proven to have better anti-
proliferative effects on cancer cells than aqueous extracts as their effects were exhibited at a 
relatively low dose. Several studies reported that the effectiveness of organic-soluble 
compounds in inhibiting or being lethal to cancerous cells is because most bioactive 
compounds are more likely to dissolve in organic solvents such as ethanol and methanol 
and only partially dissolve in polar solvents such as water (Wu et al. 2009; Saetung et al. 
2005; Ojala et al. 2000). The anti-proliferative effects of Phyllanthus could be due to the presence 
of different bioactive compounds such as galic acid, rutin, geraniin and quercetin. Majority of 
polyphenol compounds found in Phyllanthus plant possesses anti-proliferative effects. One 
such example is gallic acid being found to have anti-proliferative effects on several cancer cells 
(Huang et al. 2009; Zhong et al.2009). Their anti-proliferative effects are always associated with 
their naturally antioxidant activity. The role of these polyphenol compounds on cancer have 
well documented as their can reduces the chance of cancer development by prevent mutation 
to occur in normal cells, which cause from free radicals. Due to their protective role on normal 
cells, the anti-proliferative effects on these cells are diminished.  
4.3 Cell cycle inhibitor 
Cell is the building block of all living things in this world. The cell cycle is a critical regulator 
that controls proliferation and growth of a cell. Cell cycle is the series of events that leads the 
cells to divide and replicate. This biological process involves a sequence of molecular events 
to ensure correct transmission of the genetic material to subsequent generations. Error in 
this transmission will lead the cells to either undergo checkpoints to correct the error or 
cause cell death. Defects in regulation of cell cycle will lead modification (mutation) in 
genetics of the cell and cells which leads to tumorigenesis. An uncontrolled proliferation 
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and the ability to evade of apoptosis by mutated (cancer) cells are the hallmarks for the 
development of cancer. 
 
Compound Phyllanthus species References 
Gallic acid 
P.amarus, P.niruri, P.urinaria, 
P.watsonii, P.emblica 
Lee et al. 2011; 
Tang et al. 2010; 
Zhong et al.2009; 
Huang et al. 2009 
Corilagen 
P.amarus, P.niruri, P.urinaria, 
P.watsonii 
Lee et al. 2011; 
Tang et al. 2010; 
Zhang et al. 2004 
Geraniin 
P.amarus, P.niruri, P.urinaria, 
P.watsonii  
Lee et al. 2011; 
Tang et al. 2010; 
Zhang et al. 2004 
Caffeolquinic acid 
P.amarus, P.niruri, P.urinaria, 
P.watsonii 
Lee et al. 2011; 
Tang et al. 2010; 
Rutin 
P.amarus, P.niruri, P.urinaria, 
P.watsonii 
Lee et al. 2011; 
Tang et al. 2010 
Quercetin 
P.amarus, P.niruri, P.urinaria, 
P.watsonii, P.orbiculatus 
Tang et al. 2010; 
Huang et al. 2009; 
Nara et al., 1977 
Galloylglucopyronoside
P.amarus, P.niruri, P.urinaria, 
P.watsonii 
Lee et a. 2011;  
Tang et al. 2010 
Phyllaemblic acid P.emblica Zhang et al. 2004 
Chebulagic acid  P.emblica Zhang et al. 2004 
7V-hydroxy-
3V,4V,5,9,9V-
pentamethoxy-3,4-
methylene dioxy lignan 
P.urinaria 
Giridharan et al. 
2002 
Astragalin P.niruri, P.urinaria, P.orbiculatus Nara et al., 1977 
Phyllanthine and 
hypophyllanthine 
P.amarus 
Islam et al. 2008; 
Figueira et al.2006  
Ellagic acid P.urinaria 
Huang et al. 2011, 
2009  
Table 3. Bioactive compounds in Phyllanthus species 
Targeting the cell cycle could be an approach for anticancer agents to halt the uncontrolled 
proliferation of cancer cells and initiate them to undergo apoptosis (Sharpio & Harper, 1999). 
The cytotoxic effects of Phyllanthus extracts on growth inhibition against skin melanoma and 
prostate cancer cells in their cell cycle could partially explain their mode of activity. 
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Phyllanthus have been found to inhibit cancer growth by arresting the cancer cells at 
different cell cycle phases which later initiates them to undergo apoptosis. Phyllanthus had 
been found to arrest of different type of cancer cells in different phases. Both the aqueous 
and methanolic extracts of four different species of Phyllanthus (P.amarus, P.niruri, P.urinaria 
and P.watsonii) have been reported to induce G1-phase arrest in PC-3 cells (Tang et al. 2010). 
Arrested in G1 phase indicated that Phyllanthus extracts might disrupt the protein synthesis 
that required for PC-3 cells to enter next phase of cell cycle. In addition, these Phyllanthus 
species also disrupt the DNA synthesis on malignant melanoma MeWo cells by arrested 
them in S-phase during their cell cycle (Tang et al. 2010). Besides that, these findings reveal 
that the growth arrest of Phyllanthus treated PC-3 and MeWo cancer cells is accompanied by 
an accumulation of apoptotic cells. When the cells are arrested at a particular phase, they 
lose their uncontrolled proliferation properties and the cells will be initiated to undergo 
apoptosis. Although there are different polyphenol compounds contained in Phyllanthus, 
but they are believed to exhibits similar effects on cell cycle and led to apoptosis induction 
in treated cancer cells. For example, gallic acid and quercetin induces G1 phase cell cycle 
arrest and apoptosis in cancer cells by inactivate the phosphorylation of cdc25A/cdc25C-
cdc2 via ATM-Chk2 activation, reduces cyclin D production and activate caspase-3 activity 
(Suh et al. 2010; Agarwal et al. 2006).  
4.4 Apoptosis inducer 
There are two main cell deaths; necrotic and apoptotic processes. Apoptosis is one of the 
main types of programmed cell death (PCD) that occurs only in multicellular organisms to 
eliminate damaged or unneeded cells without local inflammation from leakage of cell 
contents. It does provide a balance between cell proliferation and elimination, as a part of 
homeostasis. Apoptosis involves a series of biochemical events, which leads to distinct 
characteristics of cell morphology and death such as cell shrinkage and membrane blebbing. 
Necrotic cell death is characterized by cellular swelling, plasma membrane rupture, cell lysis 
and induction of inflammation around the necrotic cells due to leakage of the intracellular 
contents (Chen and Wang, 2002). 
Dysregulation of the apoptotic process in human body can disrupt the equilibrium between 
cell’s growth and death and this dysregulation implicated in a variety of diseases states. 
Acquired immunodeficiency syndrome (AIDS) and neurodegenerative diseases such as 
Alzheimer’s disease are examples of diseases due to acceleration of cell death rates. 
Conversely, an inappropriate low rate of apoptotic process can give rise to autoimmune 
disorders or cancer (Fadeel & Orrenius, 2005). The genetic abnormalities of cancer cells are 
able bypass the apoptosis and escape from cell death. Thus, evasiveness of apoptosis is a 
hallmark of cancer and is critical for cancer development and the survival of a tumour cell 
(Vincent & Gatenby, 2008). 
The regulations of apoptosis on cancer cells are always associated with caspases activation. 
Caspases (cysteine-aspartic proteases or cysteine-dependent aspartate-directed proteases) are a 
family of cysteine proteases that play essential roles in apoptosis. There are two types of 
apoptotic caspases: initiator and effector caspases. Initiator caspases (caspase-2, -8, -9 and -10) 
are responsible to activate the effector caspases which initially are in an inactive pro-form. The 
active effector caspases (caspase-3, -6 and -7) will in turn cleave other proteins to initiate the 
apoptotic process to occur. In addition, these caspases will also activate other degradative 
enzymes such as DNases, which cleave the DNA into fragments in an apoptotic cell. 
The apoptotic inducer ability of Phyllanthus plant on various types of cancer cells has been 
identified (Lee et al. 2011; Tang et al. 2010; Huang et al. 2009; Zhong et al. 2009). Different 
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species of Phyllanthus plant has been shown to trigger activation of caspase-3 and -7, which 
later lead to apoptosis induction in treated cancer cells. These reveals that Phyllanthus can 
restore the apoptosis function of different cancer cells besides halting the uncontrolled 
proliferation of cell (Lee et al. 2011; Abhyankar et al. 2010; Ngamkitidechakul et al. 2010; 
Tang et al., 2010; Huang et al. 2009, 2004, 3003).  
Different species of Phyllanthus induce apoptosis in human cancer cells in different ways are 
noticed. This could be due to various bioactive compounds contained in Phyllanthus and 
might use different pathways to induce apoptosis in cancer cells. For example, P.amarus 
induces apoptosis in human breast cancer cell line, MCF-7, by increasing their levels of 
intracellular reactive oxygen species (ROS) and decreased mitochondrial membrane 
potential (MMP). Besides that, P.amarus induces expression of caspase-3 and down-regulates 
expression of Bcl-2 to allow apoptosis in treated cancer cells. The down-regulation of the 
antiapoptotic family, Bcl-2 was also noticed in Lewis lung carcinoma cells after being treated 
with a different species of Phyllanthus, P.urinaria. In addition, Phyllanthus was also shown to 
induce TNF-┙ production and inhibit expression of other antiapoptotic genes including IL-8 
and COX-2 in human hepatocarcinoma cells. Various bioactive compounds contained in 
Phyllanthus extract are believed to increase efficiency of Phyllanthus to induce apoptosis in 
cancer cells.  
4.5 Anti-metastatic effect 
Once cancer cells have transformed into malignant, they would have acquire metastatic in 
which the cells can detach from primary tumour and spread to other parts of the human 
body. Metastasis of cancer cells involves multistep processes and various cytophysiological 
changes, including disruption to adhesion interaction between cancer cells and the 
extracellular matrix (ECM) components. It also involves an over expression of proteolytic 
enzymes, such as matrix metalloproteinases (MMPs), which have the capability to degrade 
ECM components in the basal membrane of blood vessels. This allows the cancer cells to 
migrate and invade via the blood or lymphatic system into target organs and lead to the 
development of secondary tumours (Auerbach, 2000).  
Therapeutic intervention strategies to prevent metastasis have an impact on cancer 
mortality. However, development of these therapies are requires a better understanding 
and knowledge in the biology and molecular events of the metastasis process. To achieve 
this, various of assays been conducted based on molecular events of tumour metastasis in 
human body.  
The anti-metastatic properties of a compound can be defined by its inhibition on cancer 
cells’ invasion and migration. Phyllanthus have shown reduced migration ability of treated 
cancer cells by reducing the number of treated cancer cells migrating through a 8-µm pore 
size transwell filter culture plate towards a growth factor (Lee et al. 2011; Ho et al. 2010; 
Ngamkitidechakul et al. 2010). The anti-migration effect of Phyllanthus was identified 
when gallic acid showed disruption on cancer cell-cell interaction in a mechanical scratch-
wound cellular monolayer healing assay (Lee et al. 2011; Ho et al. 2010). In addition, 
Phyllanthus inhibited the invasion ability of cancer cells in a dose-dependent manner 
through the ECM as matrix barrier, which mimics the in vivo basement membrane of 
blood vessel (Lee et al. 2011; Ngamkitidechakul et al. 2010). All these indicate that 
Phyllanthus possess anti-metastatic effects by decrease cancer cells’ migration and 
invasion abilities in dose-dependent manner. 
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The anti-metastatic effect of Phyllanthus was further noticed when Phyllanthus showed 
inhibition effects on different MMPs in different type of cancer cells. Table 4 below shows 
the inhibition effects of Phyllanthus on different MMPs.  
 
MMP Phyllanthus References 
MMP-1 P.emblica 
Fujii et al. 2008; 
Chaudhuri et al. 2004 
MMP-2 P.urinaria Huang et al. 2010 
MMP-3 P.emblica Chaudhuri et al. 2004 
Table 4. Inhibition on MMP members by different Phyllanthus species 
4.6 Anti-angiogenesis effects 
Angiogenesis is a process by where a new blood vessel is formed from pre-existing blood 
vessels. It is a normal and vital process in humans’ growth and development, such as 
wound healing. In cancer, angiogenesis plays an essential role to its growth and 
development. In normal circumstances, solid tumour’s size is around 1 to 2 mm2 and not 
vascularized. However, when this tumour reaches beyond the 2 mm2, oxygen and nutrients 
are hardly diffuse to the tumour and cause cellular hypoxia. This condition will lead to the 
onset of tumour angiogenesis (Folkman, 1971). 
The balance between proangiogenic and antiangiogenic molecules is essential to maintain 
normal homeostasis in human body. Disruption of this balance would implicate to a variety of 
diseases states such as excessive (e.g. cancer and psoriasis) or inadequate (e.g. chronic wounds 
and stroke) angiogenesis. To date, angiogensis inhibitors have been reported to have less 
toxicity to normal cells and no development of drug resistance of cancer cells was notice such 
as bevacizumab, which been proven to improve the overall response including cancer time to 
progression, and survival rate. This makes the anti-angiogenic drugs highly advantageous 
over the conventional cytotoxic drugs. In addition, limited effectiveness of chemotherapy on 
advanced cancer has turn attention to these anti-angiogenic drugs and it is believed that these 
drugs will substitute the standard therapy (e.g. surgery, radiotherapy and chemotherapy).  
Endothelial cells are involved in tumour angiogenesis by forming the linings of blood vessels, 
however, these tumour vessels have abnormal morphologies and are in immature forms. 
Thus, targeting these tumour vessels can be a promising target for antiangiogenic therapy 
(Auerbach, 2003). Tumour angiogenesis is critically important for tumour growth and 
metastasis with formation of new blood vessels to supply oxygen and nutrients to cancer cells 
and also to eliminate metabolic waste products (Auerbach, 2003). Thus, both tumour 
metastasis and angiogenesis are major cause of morbidity and they remain a challenge in 
cancer treatments.  
Since the relationship between angiogenesis and cancer is clearly related where inhibition of 
angiogenesis could suppress/restrict tumour growth, this had attracted a strong interest 
from researchers worldwide to search for potential compounds that could inhibit 
angiogenesis. Although there are some successful anti-angiogenic drugs that have been 
commercialized and used in clinical and some in pre-clinical testing stage, but more 
effective and safer approaches are still required. The identification of new anticancer 
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compounds from nature has a long and successful history. Interestingly, there are some 
plants that possess proangiogenic (e.g. ┚-sitosterol and resveratrol) and antiangiogenic (e.g. 
camptothecin and combretastatin) properties and have been used in Traditional Chinese 
Medicine (TCM) from thousands of years. A wide range of plants contains compounds with 
angiogenesis modulating properties including pacific yew tree (e.g. Taxol) and Chinese tree 
camptotheca acuminate (e.g. camptothecin). 
The anti-angiogenesis properties of Phyllanthus were supported by various scientific assays. 
Phyllanthus showed no cytotoxic effect on HUVECs (human umbilicial vein endothelial 
cells) as the cells’ viability did not change. Phyllanthus also decrease the migration and 
invasion ability of HUVECs (Huang et al. 2006). The anti-angiogenic effect of Phyllanthus 
was noticeable where it inhibited capillary tube formation of endothelial cells on 
extracellular matrix, which mimics the in vivo lining of blood vessel. The anti-angiogenic 
effect of Phyllanthus was further proven by other in vivo studies where it could decrease the 
vessel density in a lung cancer animal model. Besides that, ex vivo studies using chick 
chorioallantoic membrane (CAM) assay also indicated the present of anti-angiogenesis in 
Phyllanthus (Huang et al. 2011).  
4.7 Antitumour effects 
The antitumour effects of Phyllanthus were reported in different cancer animal model 
including skin, liver and lung (Huang et al. 2006, 2003; Sancheti et al. 2005; Jeena et al. 1999). 
Currently, there are no toxicity of Phyllanthus on different experimental animal mice model 
were reported. Instead, Phyllanthus been found that possesses radioprotective activity by 
inhibit the myelosuppression and elevated the levels of antioxidant enzymes in the blood, 
liver and intestine and decrease the lipid peroxidation levels (Harikumar & Kuttan, 2007) in 
treated mice.  
All studies indicate that Phyllanthus do possess antitumour effects on different tumour by 
reducing the tumour size and increase the lifespan of cancer animal models. The antitumour 
properties of Phyllanthus should be conducted in other cancer animal models such as 
prostate cancer to prove its antitumour properties to various cancers.  
5. Conclusion 
These findings revealed that Phyllanthus plants do possess anticancer activity in a selective 
manner towards cancer cells and initiate them to undergo apoptosis. The anticancer activity 
of Phyllanthus plant on prostate cancer cells was through its regulation on cancer cell cycle 
and apoptosis induction mediated via caspases activation. The anti-metastatic and anti-
angiogenesis effects observed in Phyllanthus plant, indicate their potential in inhibiting the 
development of secondary tumour. Further investigations into the mechanism of anti-
carcinogenic, anti-metastatic, anti-angiogenesis and apoptotic regulation properties of the 
herbal plant, Phyllanthus against prostate cancer cells is required. This may create an 
opportunity for the plants to not only be designed and developed as anticancer agents, but 
also as a dietary supplement for the prevention of cancer development. However, the 
preliminary in vitro data is insufficient and less convincing due to its limitation as all 
experiments are done in an artificial environment outside a human body. Thus, an in vivo 
study using experimental prostate cancer animal model is needed to determine the 
pharmacological and toxicological data as well as anti-tumour effect of Phyllanthus, to 
provide more information on the safe use and effectiveness of this plant. 
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